GALVUS (vildagliptin), a new type
2 diabetes medication, will be
available on the PBS from 01 Aug.
The medication works in
combination with metformin, a
sulfonylurea or pioglitizone to
effectively reduce blood glucose
levels, and has been found in
combination with metformin to
deliver significant HBA1c reductions
compared to metformin plus
placebo in patients not controlled
on metformin alone.
From 01 Aug Galvus will be on
the PBS as an Authority Required
(Streamlined) item for dual oral
combination therapy.The above article was sent to subscribers in Pharmacy Daily's issue from 07 Jul 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Jul 10
PEAK pharmacy bodies are calling on the Australian Government to extend the new Commonwealth Prac Payment to pharmacy students, citing the challenges of “placement poverty” in unpaid practical placements.
AFT Pharmaceuticals is set to develop a topical treatment for keloid and hypertrophic scarring in partnership with NZ’s Massey Ventures, the commercialisation arm of Massey University, and the Gillies McIndoe Research Institute.
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.